Power of cancer drugs may see boost by targeting newly ID’d pathway
Researchers at the School of Medicine have identified a previously unknown signaling pathway cells use to protect their DNA while it is being copied. The findings suggest a way that could boost the potency of cancer therapeutics.
Vaccines’ real-world effectiveness studied with $12.5M grant from CDC
A new grant from the Centers for Disease Control and Prevention (CDC) will support research at the School of Medicine to investigate the real-world effectiveness of COVID-19 and influenza vaccines.
Planting for the future
Arboretum curator Stan Braude shares his goal for the campus landscape as well as for those who enjoy it.
Students invited to apply to free WashU Rural Scholars Academy
Washington University in St. Louis invites talented high school sophomores from rural communities in Missouri and southern Illinois to apply to the WashU Rural Scholars Academy, a free summer program that will strengthen academic and leadership skills, demystify the college application process and introduce students to Washington University, a global leader in teaching and research.
10.24.22
Images from on and around the Washington University campuses.
Inspiring hope through action
Jane Goodall made St. Louis — and Graham Chapel — a stop on her national tour to share her ‘tenacious authenticity’ and empower us to work together on behalf of our planet.
Obituary: Malik Williams, student in Arts & Sciences, 22
Malik Williams, an undergraduate student in Arts & Sciences, died Friday, Oct 7. Williams is remembered as a quiet, calming presence who loved good food, travel and nature.
10.17.22
Images from on and around the Washington University campuses.
Research offers clues for treating fatal neurological disorder in kids
Research in animals led by Washington University and the Roslin Institute in Scotland shows that supplying a vital missing enzyme helps to improve CLN1 disease, a rare but fatal brain disorder.
Investigational drug for genetic form of ALS improves disease’s molecular signs
An international phase 3 clinical trial for a drug developed to treat a rare, inherited form of amyotrophic lateral sclerosis (ALS) showed that it reduced molecular signs of the fatal disease, but at six months did not improve motor control and muscle strength, according to Washington University School of Medicine researchers.
Older Stories